Research Synthesis: Semaglutide Adverse Safety

Research Synthesis: Semaglutide Adverse Safety

Abstract

This paper synthesizes evidence on semaglutide adverse safety across 15 accepted source papers and 1436 high-confidence extracted claims.

The evidence profile contains 2 direct clinical sources, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 27 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the safety and comorbidity, cardiometabolic outcome classes, null signals in the dosing and pharmacokinetics, safety and comorbidity outcome classes, and negative signals in the safety and comorbidity outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that semaglutide adverse safety remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Introduction

This synthesis evaluates evidence on semaglutide adverse safety across 15 included source papers and 1436 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 2 direct clinical sources, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The thesis is: Across 15 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: safety comorbidity, cardiometabolic. Negative signals appear in: safety comorbidity. Null findings dominate: dosing pharmacokinetics, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

Background

The background evidence for semaglutide adverse safety is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Hamarsheh 2026, Kushner 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the safety and comorbidity, cardiometabolic outcome classes; null signals around the dosing and pharmacokinetics, safety and comorbidity outcome classes; and negative or adverse signals around the safety and comorbidity outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-semaglutide_adverse_safety-v06-DAILY-2026-06-18T20-31-59Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-18.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• semaglutide adverse safety aging
• semaglutide adverse safety older adults
• semaglutide adverse safety randomized controlled trial
• semaglutide aging
• semaglutide older adults
• semaglutide randomized controlled trial
• adverse aging
• adverse older adults
• adverse randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses semaglutide adverse safety.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 972 records in the receipt-candidate union, 260 were classified as source candidates and 15 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	972
Classified source candidates	260
No extractable claims	102
None-only claim binding	50
Mixed partial-or-none claim-binding candidates	245
Partial-only claim-binding candidates	134
Strict high-confidence sources	181
Admitted final sources	15

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, safety, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Safety and Comorbidity	n=7; claims=522	unclear signal in 2/7 sources	1 direct; 1 indirect; 5 review	limited corpus depth in this outcome class
Cardiometabolic	n=3; claims=301	unclear signal in 1/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Contextual Adjacent Evidence	n=2; claims=582	unclear signal in 1/2 sources	1 direct; 1 review	limited corpus depth in this outcome class
Safety	n=2; claims=3	unclear signal in 2/2 sources	2 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=1; claims=28	no extracted directional signal in 1/1 sources	1 protocol	single-source slice; hypothesis-generating

Results Summary

• Safety and Comorbidity: n=7; claims=522; mixed signal in 2/7 sources | directness: 1 direct; 1 indirect; 5 review; main limitation: directionally heterogeneous.
• Cardiometabolic: n=3; claims=301; mixed signal in 1/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
• Contextual Adjacent Evidence: n=2; claims=582; mixed signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.
• Safety: n=2; claims=3; mixed signal in 2/2 sources | directness: 2 review; main limitation: no direct clinical anchor.
• Dosing and Pharmacokinetics: n=1; claims=28; no extracted directional signal in 1/1 sources | directness: 1 protocol; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

Three cohort-level and model-informed sources in the corpus converge on the cardiometabolic outcome class. Buenaventura-Collazos 2024 contributes a one-year retrospective multicentric observational study, SEMACOL-REAL, conducted in Colombian adults receiving once-weekly semaglutide.

Quantitative findings diverge in direction across the three sources. Strathe 2026 reaches P < 0.01 in its adolescent dose-extrapolation model, with an effect direction labeled mixed. the evidence synthesis carries the full per-study endpoint p-value matrix so the reader can inspect each study × endpoint tuple directly.

By contrast, the unclear effect direction in McGowan 2025 reflects the review's aggregation of heterogeneous RCTs, where individual trial improvements on lipid profile, blood pressure, HbA1c, and fasting plasma glucose are pooled against null or conflicting comparators. The mechanistic substrate underlying this functional finding — incretin-driven reductions in glucagon, slowing of gastric emptying, and centrally mediated satiety — is consistent across the three sources even where statistical directionality diverges.

Within the corpus, the principal tension is between the single positive real-world signal from Buenaventura-Collazos 2024 (P < 0.001, P = 0.008) and the mixed/unclear pooled directionality in McGowan 2025 and Strathe 2026. The disagreement is best read as a difference between a single-cohort effectiveness study and aggregated efficacy reviews plus a pharmacokinetic extrapolation; it is not a contradiction of underlying biology but a disagreement about how to weight direct clinical observation versus pooled indirect evidence. The cardiometabolic case for semaglutide therefore rests on a positive observational anchor (Buenaventura-Collazos 2024) with supportive but directionally ambiguous modeling and review evidence (Strathe 2026; McGowan 2025).

Contextual Adjacent Evidence Outcomes

Hamarsheh 2026 is a network meta-analysis of randomized clinical trials evaluating the comparative effectiveness of CagriSema, semaglutide, cagrilintide, and tirzepatide in adults with overweight or obesity, with outcomes spanning percent body weight, absolute weight, waist circumference, and BMI change. The breadth of significant comparator-level contrasts within Hamarsheh 2026 establishes semaglutide's place within a tightly contested incretin/glucagon co-agonist landscape, while the single non-significant contrast signals that not every between-agent difference reaches statistical separation in this network.

Karagiannis 2024 is a systematic review and network meta-analysis of subcutaneously administered tirzepatide versus semaglutide in adults with type 2 diabetes, sourced from PubMed and Cochrane searches up to 11 November 2023 and restricted to randomized controlled trials with an intervention duration of at least 12 weeks. The review-level synthesis aggregates indirect comparisons across an RCT network rather than reporting a per-arm endpoint p-value table, and no discrete p-values are surfaced from Karagiannis 2024 itself. Functionally, Karagiannis 2024 functions as an indirectness anchor: the same molecule pair is examined, but the population (type 2 diabetes rather than obesity) and the endpoint architecture shift the evidentiary weight from anthropometric outcomes to glycemic and safety comparators.

Mechanistically, the curated corpus does not provide tissue-level or receptor-level explanations for the between-agent differences seen in Hamarsheh 2026 or Karagiannis 2024; the integrating signal is therefore carried by clinical RCT comparisons rather than preclinical substrate. Because Hamarsheh 2026 is direct and Karagiannis 2024 is review-level on an overlapping but distinct population, the two should not be averaged into a single pooled estimate; their contributions are complementary rather than redundant.

This disagreement is best read as a scope mismatch: Hamarsheh 2026 interrogates obesity-related anthropometric endpoints while Karagiannis 2024 interrogates diabetes-population safety and efficacy, and the two should be interpreted along their respective population axes rather than collapsed into a single comparative statement.

Dosing and Pharmacokinetics Outcomes

Dosing and pharmacokinetic characterization of semaglutide in non-diabetic, non-obesity populations remains protocol-stage rather than completed-trial evidence. Kimura 2025 contributes the principal design in this outcome class as a randomised, double-blind, placebo-controlled protocol evaluating oral semaglutide tablets in patients with Parkinson's disease at Hoehn & Yahr stages 1-2.5 across eight sites in Japan, with the explicit remit of establishing the disease-modifying effect, safety, and optimal dose (MOST-ABLE study). The protocol framework embeds both efficacy and safety endpoints, and is positioned to generate the dose-finding signal that currently is absent from the curated corpus.

Quantitatively, the Kimura 2025 protocol does not yet supply p-values, effect sizes, or pharmacokinetic parameter estimates; the only reportable design numerics are the target population (Parkinson's disease, Hoehn & Yahr 1-2.5) and the multi-site Japanese setting. This absence of completed-trial data is itself a finding: within the curated corpus, the dosing pharmacokinetics outcome class is dominated by null or pre-randomisation material, and downstream synthesis cannot claim a calibrated dose-response for adverse safety without referencing the evidence synthesis endpoint rows once the protocol reports.

Preclinical data suggest that oral semaglutide's exposure profile differs from subcutaneous administration in ways that plausibly shift gastrointestinal and central adverse-event thresholds, but the curated corpus does not include a clinical pharmacokinetic arm with reported Cmax, AUC, or tmax values to confirm or refute that expectation in the Parkinson's disease population.

Within-corpus tensions on this outcome class are minimal because only one source contributes; the principal internal tension is the gap between the protocol's ambitious multi-endpoint scope and the absence of any interim or completed readout that would adjudicate the safety-versus-efficacy dose question. By contrast with the safety comorbidity outcome class, which contains multiple competing signals, dosing pharmacokinetics presents as a single-source design artefact awaiting results, and any near-term synthesis claim for adverse safety must therefore be conditioned on forthcoming trial output rather than the present evidence stack.

Safety Outcomes

The safety corpus assembled for this synthesis draws on two systematic reviews that together constitute the curated evidence base for semaglutide's adverse-event profile, with no additional primary randomized trials included in the working set. Ahmed 2026, by contrast, is a systematic review, meta-analysis and meta-regression comparing the efficacy and safety of cagrilintide and cagrisema versus semaglutide as anti-obesity medications, situating semaglutide as an active comparator in a head-to-head safety review rather than as the index intervention. Across both reviews, the study designs are systematic-review level, both outcome classes are tagged safety, and directness is coded as review rather than direct RCT, meaning the relevant numerics flow upward from underlying primary trials rather than from a single prospectively enrolled population. No follow-up duration, sample size, dose, or primary endpoint can be attached to a single enrolled cohort in either review because no canonical trial identifier is present in the corpus for these two records.

The available quantitative content from the two safety reviews is comparatively sparse but directionally consistent on the dominant safety signal. Moiz 2024 reports that the risk of gastrointestinal adverse events was higher in participants who took semaglutide than placebo, framing the gastrointestinal organ class as the principal tolerability burden rather than identifying a single p-value, hazard ratio, or odds ratio from within the source excerpt. Ahmed 2026, in its comparator-based framing, reports that overall and serious adverse events were comparable between cagrisema and semaglutide, while combination therapy increased administration-related adverse events relative to semaglutide monotherapy, again without a single attributable p-value or effect size inside the source text. Because p values fields are empty for both reviews, no individual test statistic can be cited as the quantitative anchor of the safety subsection, and the synthesis must rely on the qualitative directional language recorded in the source theses. This constraint is itself reportable: the curated safety evidence for semaglutide's anti-aging repositioning is dominated by review-level direction-of-effect statements rather than by traceable per-study p-values, which has direct implications for how confidently downstream mechanism claims can be staged.

Mechanistically, the gastrointestinal-dominant adverse-event pattern captured in Moiz 2024 aligns with the known incretin pathway effects of semaglutide on gastric emptying and central appetite-regulating nuclei, which is why nausea, vomiting, early satiety, and diarrhea cluster as the dominant clinical complaints in the broader GLP-1 receptor agonist class. In human-readable terms, the safety evidence base therefore consists of clinical RCT data synthesized through two independent systematic reviews, with mechanistic human studies and preclinical data framing the incretin pharmacology but not supplying new quantitative anchors in the present corpus. This functional pattern — comparable serious events but additive administration burden — is the mechanism-relevant signature that any future anti-aging repositioning of semaglutide must inherit.

The within-corpus tension on safety is subtle but present, and it should be named explicitly rather than smoothed over. Ahmed 2026, in contrast, frames semaglutide as a comparator and reports overall and serious adverse events comparable to cagrisema, which is a null finding on the serious-event axis even though administration-related events rise with combination therapy. These two readings are not strictly contradictory — Moiz 2024 emphasizes gastrointestinal versus placebo and Ahmed 2026 emphasizes serious events versus combination — but they do illustrate that the magnitude and clinical weight of the semaglutide safety signal depend on which comparator the reviewer selects. The picked thesis characterizes the overall evidence base as context-dependent with positive signals on safety comorbidity, negative signals on safety comorbidity, and null findings that dominate the dosing pharmacokinetics and safety comorbidity axes, and the two curated reviews jointly instantiate that mixed pattern rather than resolving it. Readers should therefore interpret the Semaglutide evidence as a tolerability profile that is dominated by gastrointestinal organ-class events at the individual-patient level while remaining non-inferior on serious-event endpoints when benchmarked against combination anti-obesity pharmacotherapy.

Safety and Comorbidity Outcomes

Seven curated evidence sources address safety comorbidity under semaglutide exposure, spanning one direct randomized controlled trial, two meta-analyses, and four observational or review-level syntheses. In the SELECT study (Kushner 2025), once-weekly subcutaneous semaglutide 2.4 mg was compared with placebo for safety beyond major adverse cardiovascular events in adults, providing the only direct randomized human RCT signal in the corpus. By contrast, Tan 2022 and Safwan 2025 frame gastrointestinal and systemic adverse events across obesity and diabetes populations at the meta-analytic level, while Oe 2024, Abdullah 2025, Feier 2024, and Huang 2024 contribute indirect or review-level safety evidence in older adults, chronic kidney disease, thyroid surveillance, and type 2 diabetes, respectively.

Within-corpus tensions are most visible along two axes. The clinical RCT therefore anchors cardiovascular reassurance, while gastrointestinal and thyroid conclusions remain dependent on observational and meta-analytic evidence with smaller effect-size certainty.

Cross-Domain Synthesis

A first load-bearing tension sits between the direct SELECT safety RCT (Kushner 2025) and the aggregated safety reviews (Feier 2024, Huang 2024, Safwan 2025, Abdullah 2025, Tan 2022, Moiz 2024, Ahmed 2026). Kushner 2025 reports a positive safety profile for once-weekly subcutaneous semaglutide 2.4 mg versus placebo on top of standard care, with non-inferior event rates for most adverse-event categories (P < 0.001 for some pre-specified contrasts; P = 0.76 for one key safety comparison). The mechanism for disagreement is directness: SELECT enrolled a cardiovascular-risk population and ascertained events under rigorous RCT surveillance, whereas the meta-analyses pool heterogeneous trials, doses, and populations. The boundary condition is straightforward — within a high-risk, monitored population SELECT-style, semaglutide's hard-endpoint safety looks reassuring; in pooled real-world denominators, GI toxicity emerges. Resolving evidence would require a head-to-head trial enrolling non-SELECT-style patients to test whether GI-class signals attenuate under active surveillance.

The mechanism for divergence is population: Tan 2022 pooled weight-loss trials in non-diabetic adults and observed substantially elevated GI discontinuation, whereas Huang 2024 pooled diabetes trials and the aggregate did not signal harm. This is not a real contradiction so much as a population-stratified boundary — adverse-event rates, particularly GI events, appear higher in non-diabetic obesity populations, where the comparator is placebo and background medication burden is lower, than in diabetic populations, where gastrointestinal symptoms from concurrent metformin and other agents may mask the semaglutide-attributable signal. Resolving evidence would require stratified reporting — adverse-event incidence per patient-year stratified by diabetes status, dose, and concomitant metformin (which carries an upper daily dose of 2000 mg per ADA 2024) — rather than pooled meta-analytic averages.

Another tension runs between clinical safety outcomes and the contextual other mechanistic/biomarker class represented by Hamarsheh 2026 and Karagiannis 2024. Hamarsheh 2026 is a network meta-analysis of weight and metabolic outcomes across CagriSegma, semaglutide, cagrilintide, and tirzepatide, with multiple pre-specified contrasts reaching statistical significance (P < 0.0001, P = 0.030, P = 0.048, P = 0.043, P = 0.004, P = 0.021, P < 0.001, P = 0.0055) and some not (P > 0.05), reflecting a direct mechanistic/biomarker endpoint focus rather than hard safety ascertainment. The risk is that the biomarker wins reported in mechanistic RCTs — anthropometric and glycemic reductions — may be cited as evidence of overall safety superiority, conflating surrogate improvement with hard safety. Methodological caution is warranted: surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). Resolving evidence would require biomarker trials with hard-outcome follow-up extensions.

Another tension pits the cardiometabolic outcome class (McGowan 2025, Buenaventura-Collazos 2024, Strathe 2026) against the safety comorbidity class (Kushner 2025, Abdullah 2025). The tension with Kushner 2025 is that cardiometabolic surrogate wins are well-documented, but safety comorbidity ascertainment under SELECT conditions may not generalize to adolescents, older adults, or CKD patients. The boundary condition is organ-specific: cardiac and renal populations differ from obesity-only populations in baseline comorbidity. Resolving evidence would be organ-stratified trials in CKD, geriatric (Oe 2024 in patients >65), and adolescent (Strathe 2026) populations with parallel safety ascertainment.

A fifth and final tension connects the dosing pharmacokinetics class — represented by Kimura 2025, the MOST-ABLE oral-semaglutide Parkinson's disease protocol (a D1 protocol, null effect direction) — with both the safety comorbidity class (Kushner 2025) and the contextual other mechanistic class (Hamarsheh 2026). The temptation in an anti-aging synthesis is to fuse Parkinson's-protocol pharmacology with the broader safety record, but this conflates an indication hypothesis with an outcome: safety comorbidity in non-Parkinsonian populations (cardiovascular, obesity, diabetes, CKD) tells us nothing about disease modification in neurodegenerative disease. Kushner 2025's SELECT-style safety data should not be cross-cited to support Parkinson's repurposing. Mechanistic biomarker evidence (Hamarsheh 2026) likewise addresses metabolic endpoints, not neurodegeneration. The boundary condition is that semaglutide's safety and efficacy are indication-specific; no cross-indication inference is supported. Resolving evidence would be the MOST-ABLE trial itself and parallel head-to-head studies in Parkinson's, Alzheimer's, and related indications, with hard neurological endpoints rather than surrogate glycemic measures. Until those data mature, the Semaglutide profile in non-metabolic indications remains an open question that the current corpus cannot answer.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 15 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: safety comorbidity, cardiometabolic. Negative signals appear in: safety comorbidity. Null findings dominate: dosing pharmacokinetics, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 15 included sources. The evidence-tier distribution is: B1 (n=6), B2 (n=6), A1 (n=2), D1 (n=1). By directness, the breakdown is: review (n=9), indirect (n=3), direct (n=2), protocol (n=1). 10 of 15 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 2 distinct summaries across the source set: adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Because no source in the corpus enrolled normoglycemic, lean, older adults for a mortality endpoint, the safety claim cannot be extrapolated beyond the SELECT-like cardiovascular-risk population, and any anti-aging framing is unsupported by the sources on hand. The absence of a dedicated hard-outcome trial in the target anti-aging population is the single most consequential gap in the evidence base and should be treated as a structural limitation rather than a peripheral caveat.

Several safety outcomes rest on a single direct source and therefore cannot be internally replicated within the corpus. The SELECT safety reanalysis (Kushner 2025) is the only direct RCT source for safety comorbidity, so any safety conclusion that is not also represented in an independent direct RCT inherits a single-trial generalization risk. Where the direct and review evidence diverge — for example, the null direction reported by Huang 2024 versus the negative gastrointestinal direction reported by Tan 2022 in the safety comorbidity class — the single-trial generalization problem is amplified because the disagreement cannot be adjudicated by a second direct source within the corpus.

The enrolled populations cluster heavily on type 2 diabetes with overweight or obesity, which truncates external validity for older non-diabetic users, adolescents, and patients with advanced chronic kidney disease or neurodegenerative disease.

Endpoint scope is narrower than the question the synthesis is asked to address.

A mechanism-to-clinic gap separates the most explicit mechanistic source from the clinical safety sources. Because mechanistic plausibility is being inferred from a non-safety outcome class, the bridge to clinical safety must respect the Ioannidis 2005 caution that surrogate endpoint associations do not guarantee hard-outcome validity. Until a direct safety RCT in the target anti-aging population is added to the corpus, the mechanistic-to-clinical leap remains a structural limitation of the synthesis and the safety conclusions in safety comorbidity should be treated as conditional on this gap.

Conclusion

For semaglutide adverse safety, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support semaglutide adverse safety as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 15 included sources on Semaglutide Adverse Safety across 5 outcome classes and 27 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 15 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: safety comorbidity, cardiometabolic. Negative signals appear in: safety comorbidity. Null findings dominate: dosing pharmacokinetics, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs negative between Huang 2024 and Tan 2022 on safety and comorbidity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Karagiannis 2024, Abdullah 2025, Safwan 2025, Tan 2022, Ahmed 2026) emphasize convergent signals on Semaglutide Adverse Safety. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	3	mixed, positive, unclear	direct interventional hard-endpoint gap
safety	0	2	unclear	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	1	1	mixed, unclear	replication gap
safety and comorbidity	1	6	mixed, negative, null, positive, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: mixed, positive, unclear
P2	safety: direct interventional hard-endpoint gap	0 direct and 2 indirect sources; direction profile: unclear
P3	dosing and pharmacokinetics: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P4	contextual adjacent evidence: replication gap	1 direct and 1 indirect sources; direction profile: mixed, unclear
P5	safety and comorbidity: conflict-resolution gap	1 direct and 6 indirect sources; direction profile: mixed, negative, null, positive, unclear

Next-Study Design Recommendation

The next high-yield study for Semaglutide Adverse Safety should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Hamarsheh 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001.
• Kushner 2025; tier=A1; directness=direct; endpoint=safety comorbidity; direction=positive; representative statistic=P < 0.001.
• Karagiannis 2024; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear.
• Abdullah 2025; tier=B1; directness=review; endpoint=safety comorbidity; direction=mixed; representative statistic=P < 0.00001.
• Safwan 2025; tier=B1; directness=review; endpoint=safety comorbidity; direction=mixed; representative statistic=P < 0.01.
• Tan 2022; tier=B1; directness=review; endpoint=safety comorbidity; direction=negative; representative statistic=P < 0.00001.
• Ahmed 2026; tier=B1; directness=review; endpoint=safety; direction=unclear.
• Moiz 2024; tier=B1; directness=review; endpoint=safety; direction=unclear.
• McGowan 2025; tier=B2; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.
• Oe 2024; tier=B2; directness=indirect; endpoint=safety comorbidity; direction=unclear; representative statistic=P < 0.001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=379.
• Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial: outcome=safety comorbidity; directness=direct; tier=A1; direction=positive; claims=95.
• Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=203.
• Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis: outcome=safety comorbidity; directness=review; tier=B1; direction=mixed; claims=102.
• Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis: outcome=safety comorbidity; directness=review; tier=B1; direction=mixed; claims=88.
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis *: outcome=safety comorbidity; directness=review; tier=B1; direction=negative; claims=53.
• Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.: outcome=safety; directness=review; tier=B1; direction=unclear; claims=2.
• Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.: outcome=safety; directness=review; tier=B1; direction=unclear; claims=1.
• A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=147.
• Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study): outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=110.
• Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=109.
• Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review: outcome=safety comorbidity; directness=review; tier=B2; direction=unclear; claims=62.
• Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=45.
• Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=12.
• Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study: outcome=dosing pharmacokinetics; directness=protocol; tier=D1; direction=null; claims=28.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs negative: Huang 2024 vs Tan 2022; Tan 2022 (negative on safety comorbidity) vs Huang 2024 (null on safety comorbidity) — partial conflict
• Severity 3 indirectness gap: Feier 2024 vs Kushner 2025; Kushner 2025 (direct, A1) vs Feier 2024 (review) on safety comorbidity — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Huang 2024 vs Kushner 2025; Kushner 2025 (direct, A1) vs Huang 2024 (review) on safety comorbidity — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Karagiannis 2024 vs Hamarsheh 2026; Hamarsheh 2026 (direct, A1) vs Karagiannis 2024 (review) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Oe 2024 vs Kushner 2025; Kushner 2025 (direct, A1) vs Oe 2024 (indirect) on safety comorbidity — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kushner 2025 vs Safwan 2025; Kushner 2025 (direct, A1) vs Safwan 2025 (review) on safety comorbidity — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kushner 2025 vs Abdullah 2025; Kushner 2025 (direct, A1) vs Abdullah 2025 (review) on safety comorbidity — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kushner 2025 vs Tan 2022; Kushner 2025 (direct, A1) vs Tan 2022 (review) on safety comorbidity — direct vs indirect must be kept separate

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Studenski 2011, Cesari 2009, Perera 2006, WHO 2000, Bohannon 1997, Cruz-Jentoft 2019, Tinetti 1988.

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Tancredi 2015.

References

• Hamarsheh 2026. Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70248. PMID: 42207966.
• Karagiannis 2024. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia, 2024. DOI: 10.1007/s00125-024-06144-1. PMID: 38613667.
• McGowan 2025. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine, 2025. DOI: 10.1038/s41591-025-03978-z. PMID: 41039116.
• Oe 2024. Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study). BMC Endocrine Disorders, 2024. DOI: 10.1186/s12902-024-01658-6. PMID: 39049060.
• Strathe 2026. Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach. Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70678. PMID: 41906858.
• Abdullah 2025. Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 2025. DOI: 10.1002/edm2.70136. PMID: 41276951.
• Kushner 2025. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring, Md.), 2025. DOI: 10.1002/oby.24222. PMID: 39948761.
• Safwan 2025. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Annals of Saudi Medicine, 2025. DOI: 10.5144/0256-4947.2025.129. PMID: 40189856.
• Feier 2024. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25084346. PMID: 38673931.
• Tan 2022. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis *. Journal of the ASEAN Federation of Endocrine Societies, 2022. DOI: 10.15605/jafes.037.02.14. PMID: 36578889.
• Buenaventura-Collazos 2024. Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia. Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1372992. PMID: 38982987.
• Kimura 2025. Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study. BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-112318. PMID: 41448692.
• Huang 2024. Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis. Medicine, 2024. DOI: 10.1097/MD.0000000000038236. PMID: 38787986.
• Ahmed 2026. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes Obes Metab, 2026. DOI: 10.1111/dom.70667. PMID: 41834765.
• Moiz 2024. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol, 2024. DOI: 10.1016/j.amjcard.2024.04.041. PMID: 38679221.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Tinetti 1988. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707. DOI: 10.1056/NEJM198812293192604. PMID: 3205267.
• Tancredi 2015. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. DOI: 10.1056/NEJMoa1504347. PMID: 26510021.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.